JDRF’s Commitment to Transforming T1D Care for Children

For decades, Type 1 diabetes (T1D) has placed an extraordinary burden on children and their families. Managing blood glucose levels around the clock, calculating insulin doses for every meal and activity, and constantly monitoring for dangerous highs and lows can feel overwhelming. The Juvenile Diabetes Research Foundation (JDRF) has been at the forefront of changing that narrative. Through aggressive funding of research, strategic partnerships with technology companies, and advocacy for regulatory and insurance reforms, JDRF is working to make life with T1D not just manageable but truly less intrusive. The foundation’s focus on innovative technologies—from smarter pumps to artificial pancreas systems and connected apps—is reshaping what it means to be a child living with this chronic condition. This article explores the breadth of JDRF’s efforts and the tangible impact these innovations have on quality of life for young patients.

Pioneering Advancements in Insulin Delivery

Insulin delivery has come a long way from the days of multiple daily injections with syringes. JDRF has been instrumental in pushing the development and adoption of advanced insulin pumps and, more critically, closed-loop systems often called “artificial pancreas” devices. These systems combine a continuous glucose monitor (CGM) with an insulin pump and a control algorithm that automatically adjusts insulin delivery based on real-time glucose readings.

From Open-Loop to Hybrid Closed-Loop Systems

Early insulin pumps required the user to program basal rates and deliver boluses manually. The first generation of hybrid closed-loop systems, such as the Medtronic MiniMed 670G and later the 780G, Tandem t:slim X2 with Control-IQ, and Omnipod 5, represent a quantum leap. These devices automatically increase or decrease basal insulin to keep glucose in a target range and can even deliver correction boluses. JDRF provided critical early funding for algorithm development and clinical trials that demonstrated the safety and efficacy of these systems in children as young as two years old.

The result: children using hybrid closed-loop systems spend significantly more time in the target glucose range (70–180 mg/dL) and experience fewer episodes of severe hypoglycemia or diabetic ketoacidosis. Parents report dramatically reduced anxiety at night because the system can respond to a dropping glucose level before it becomes dangerous. JDRF continues to fund next-generation systems that aim for full automation—where the user only needs to announce meals or, eventually, not even that.

The Role of Interoperability and Non-Profit Standards

JDRF also championed the concept of an interoperable artificial pancreas. By pushing for standards that allowed components from different manufacturers to work together, the foundation helped lower barriers to innovation. This approach encouraged companies like Dexcom and Tandem to create integrated systems, and it opened the door for community-built open-source projects like Loop, which JDRF cautiously supports as a bridge until commercial options are widely available. The foundation’s Artificial Pancreas Program remains one of its largest and most successful initiatives.

Continuous Glucose Monitoring: A Window into Real-Time Control

Before CGMs, children with T1D relied on fingerstick blood tests that gave only a snapshot of glucose at a single moment. JDRF recognized early that frequent, actionable data was the key to better control and fewer emergencies. The foundation funded landmark studies that proved CGM use leads to lower A1c levels and fewer hypoglycemic events, especially in children and adolescents who are often less engaged in their own care.

Device Evolution and Pediatric Usability

Today’s CGM systems—the Dexcom G6 and G7, Freestyle Libre 2 and 3, and Medtronic Guardian—offer features specifically designed for children: waterproof sensors for swimming and bathing, disposable all-in-one sensors that don’t require calibration, and optional smartphone displays with remote monitoring. JDRF has pushed for approval of these devices for the youngest patients. For example, the Dexcom G6 is now approved for children aged 2 and older, and the Freestyle Libre 2 for ages 4 and older. This means even toddlers can benefit from continuous glucose data without the trauma of repeated fingersticks.

Remote monitoring is perhaps the single most transformative feature for families. Parents can see their child’s glucose levels on their own phone—even while at work or sleeping—and receive alarms for dangerous highs and lows. This capability reduces the constant mental burden and has been shown to improve parental sleep quality and overall family wellbeing. JDRF continues to advocate for insurance coverage of CGMs for all children with T1D, recognizing that cost remains a barrier. JDRF’s advocacy team works with state and federal lawmakers to expand access through Medicaid and private insurance mandates.

Smart Technologies and Connected Apps

The smartphone has become an indispensable tool in T1D management. JDRF has collaborated with software developers, academic medical centers, and tech giants to create a suite of apps that integrate with CGM and pump data, help with carbohydrate counting, and provide decision support.

Data Integration and Bolus Calculators

Apps like mySugr, Glooko, and Tidepool aggregate data from multiple devices into a single dashboard. For children and teens, this means no more pencil-and-paper logbooks. These platforms generate reports that can be shared with the care team, identifying patterns and optimizing insulin doses. JDRF funded early development of T1D-specific machine learning algorithms that power bolus calculators and predictive low-glucose suspend features.

Wearable devices, such as smartwatches, now allow children to view their glucose levels discreetly without pulling out a phone. The Apple Watch, for instance, can display Dexcom glucose readings and even send alerts to a parent’s phone while the child is at school. JDRF’s research into wearable integration has helped accelerate these features from concept to reality.

Gamification and Behavior Change

Recognizing that adolescents often struggle with adherence, JDRF has supported the development of gamified apps that reward healthy behaviors. For example, apps that award points for checking glucose before meals or for staying in range can improve engagement. While early evidence is modest, JDRF continues to explore behavioral design as a complement to hardware innovation.

Research Frontiers: Implantables, Immunotherapy, and the Bio-Artificial Pancreas

JDRF’s vision extends far beyond current technologies. The foundation funds a robust pipeline of research aimed at making insulin delivery even more autonomous and, ultimately, finding a biological cure. While a cure remains the ultimate goal for many families, JDRF’s current strategy emphasizes “overcoming T1D” through a combination of prevention, restoration of beta cell function, and advanced technology.

Implantable and Ingestible Devices

Several research teams, supported by JDRF grants, are developing implantable glucose sensors that last months or years and communicate wirelessly with an external controller. These could eliminate the need for frequent sensor changes. Similarly, work is underway on implantable pumps that deliver insulin directly into the peritoneal cavity, mimicking the natural delivery route more closely than subcutaneous injection. JDRF also funds early-stage work on smart insulin patches and even injectable “smart” insulin that activates only when glucose levels rise. The JDRF Research Portfolio provides an overview of these cutting-edge projects.

The Bio-Artificial Pancreas

One of the most promising long-term technology goals is the bio-artificial pancreas. This involves encapsulating insulin-producing beta cells derived from stem cells in a protective membrane that shields them from the immune system while allowing glucose and insulin to pass through. JDRF has been a major funder of ViaCyte (now part of Vertex Pharmaceuticals) and other companies working on this approach. Early clinical trials have shown that encapsulated cells can function for months, reducing the amount of external insulin needed. If successful, this could provide a functional cure that avoids the need for lifelong immunosuppression. JDRF’s investment in this area is a testament to its commitment to both incremental and transformative solutions.

Improving Quality of Life: Measurable Outcomes and Real Stories

Beyond the technical achievements, the ultimate measure of success for JDRF is how these technologies change daily life for children and their families. The data show remarkable improvements.

Clinical Outcomes

Children using hybrid closed-loop systems typically achieve an A1c reduction of 0.5–1.0 percentage points and increase their time-in-range by 2–3 hours per day. More importantly, the incidence of severe hypoglycemia—the kind that causes seizures or loss of consciousness—drops by 50–70%. This is not just a number on a chart; it means fewer emergency room visits, less missed school, and lower healthcare costs. JDRF-funded studies have also shown that these benefits are sustained over years, not just during clinical trials.

Psychosocial and Emotional Impact

A child who no longer wakes up multiple times each night to treat a low blood sugar sleeps better, performs better in school, and has more energy for friends and activities. A parent who can see their child’s glucose on a phone screen from anywhere worries less and can be more present at work. JDRF-sponsored surveys have found that 9 out of 10 parents of children using CGM with remote monitoring report reduced anxiety. Children themselves say they feel more in control and less defined by their diabetes. JDRF’s own quality-of-life resources highlight these real-world impacts.

School and Physical Activity

Technology also enables normal childhood experiences. Children on a closed-loop system can go to sleepover camp, participate in competitive sports, and eat meals without the constant need for fingersticks and injections. JDRF provides training and materials for school nurses to help them manage these devices, reducing barriers to inclusion. The foundation also works with organizations like the American Diabetes Association to ensure that children aren’t excluded from school activities or playground time due to diabetes management.

Advocacy and Community Support: Making Innovation Accessible

Developing great technology is only part of the battle. Ensuring that every child who can benefit actually receives it requires a sustained advocacy effort. JDRF’s advocacy arm is among the most effective in the disease community.

Insurance and Regulatory Wins

JDRF has played a pivotal role in convincing the FDA to approve devices for children and to create a streamlined path for closed-loop systems. The foundation’s Government Relations team has secured coverage of CGMs and insulin pumps through Medicare, state Medicaid programs, and many private insurers. In 2023, JDRF helped achieve federal legislation requiring state Medicaid programs to cover CGM for all children with T1D. This directly translates to real families getting the technology they need, regardless of income.

TypeOne Nation and Bag of Hope

At the grassroots level, JDRF runs TypeOne Nation, a program that provides personalized education and support to newly diagnosed families. The Bag of Hope includes informational materials, a copy of the book “Understanding Diabetes,” and connections to local support groups. JDRF also holds annual research summits and tech showcases where families can see new devices and talk to experts. These community-building efforts are critical for helping families navigate a rapidly evolving technology landscape.

The Future: Toward Fully Autonomous Systems and Beyond

JDRF’s mission statement speaks of a world without T1D. While a cure remains the long-term goal, the organization continues to push for technologies that make daily management invisible. The next decade will likely see fully autonomous closed-loop systems that require no meal announcement and use dual-hormone (insulin and glucagon) delivery to further reduce risks. JDRF is already funding multi-hormone pumps and, as mentioned, the encapsulation of stem-cell-derived islets.

Artificial Intelligence and Data Science

JDRF has invested in the T1D Exchange Quality Improvement Collaborative, which uses real-world data from tens of thousands of patients to identify best practices. Machine learning models trained on CGM and pump data can predict glucose trends hours in advance, allowing preemptive adjustments. JDRF also supports the development of digital health platforms that connect patients with clinical trials, accelerating the pace of innovation. As artificial intelligence continues to mature, the potential for personalized, predictive, and proactive diabetes management is enormous.

The challenges of Type 1 diabetes in childhood are daunting, but the trajectory is unmistakably positive. Thanks to JDRF’s relentless dedication to innovation, advocacy, and community support, children today have more freedom, better health, and greater hope than ever before. The organization’s work is not just about technology—it is about reclaiming childhood from the constant demands of a chronic disease. For families living with T1D, that is the most meaningful outcome of all.